Melatonin Effects on Persistent Pulmonary Hypertension Induced Hypoxia
Keywords:
Melatonin, Newborn, Persistent Pulmonary Hypertension, High-mobility group box-1, HypoxiaAbstract
Background: Tissue hypoxia and insufficient perfusion can cause end organ damage in the systemic condition known as persistent pulmonary hypertension of neonates (PPHN), which has several causes. To diagnose hypoxia caused by PPHN and evaluate its improvement, changes in the high-mobility group box-1 (HMGB-1) protein can be used as a preliminary diagnostic marker. As a biomarker for disease severity and treatment response prediction, it may be pivotal in the hypoxia- and inflammatory-related pathophysiology of PPHN. The purpose of this study was to measure serum levels of high mobility group box-1 protein to determine the effects of melatonin in PPHN-induced hypoxia.
Methods: This randomized-control study was conducted on 80 neonates ≥ 36 weeks of gestation, diagnosed with persistent pulmonary hypertension. The patients were split into two equal groups: Group I was given Melatonin, whereas group II got a placebo.
Results: Melatonin significantly decreased serum HMGB levels compared to the control group. The melatonin group had a much shorter duration of mechanical breathing, oxygen support, and Neonatal Intensive Care Unit (NICU) stay compared to the control group. Also, Estimated Systolic Pulmonary Arterial Pressure (ESPAP) was significantly lower in the melatonin group than in control group.
Conclusions: Melatonin can be used as an adjuvant therapy in PPHN and Hypoxic respiratory failure (HRF). Serum HMGB-1 levels can be used to prove melatonin’s positive effects in PPHN
Downloads
References
[1] S. Timberline, A. Bhatt, S. Sunderji, D. J. Tancredi, S. Lakshminrusimha, and H. Siefkes, “Novel scoring tool of hypoxemic respiratory failure and pulmonary hypertension for defining severity of persistent pulmonary hypertension of newborn,” J. Perinatol., vol. 43, no. 10, pp. 1281–1287, 2023, doi: 10.1038/s41372-023-01762-w.
[2] H. M. L. S. Siefkes, “Management of systemic hypotension in term infants with persistent pulmonary hypertension of the newborn: an illustrated review,” Arch. Dis. Child. Fetal Neonatal Ed., vol. 106, no. 4, pp. 446–455, Jul. 2021, doi.org/10.3390/children11040490.
[3] D. Liu, R. P. Ceddia, W. Zhang, F. Shi, H. Fang, and S. Collins, “Discovery of another mechanism for the inhibition of particulate guanylyl cyclases by the natriuretic peptide clearance receptor,” Proc. Natl. Acad. Sci. U. S. A., vol. 120, no. 28, p. e2307882120, Jul. 2023, doi: 10.1073/PNAS.2307882120.
[4] E. G. Figueroa et al., “Beneficial effects of melatonin on prostanoids pathways in pulmonary hypertensive neonates,” Vascul. Pharmacol., vol. 138, no. March, 2021, doi: 10.1016/j.vph.2021.106853.
[5] T. Nakamura et al., “Measurement of plasma concentration of high mobility group box1 (HMGB1) in early neonates and evaluation of its usefulness,” Clin. Chim. Acta, vol. 61, no. 5, pp. 1–28, 2022, doi: 10.1016/j.plabm.2023.e00327.
[6] B. Mathew and S. Lakshminrusimha, “Review persistent pulmonary hypertension in the newborn,” Children, vol. 4, no. 8, 2017, doi: 10.3390/children4080063.
[7] M. Jankowich, B. A. Maron, and G. Choudhary, “Mildly elevated pulmonary artery systolic pressure on echocardiography: bridging the gap in current guidelines,” Lancet Respir. Med., vol. 9, no. 10, pp. 1185–1191, 2021, doi: 10.1016/S2213-2600(21)00072-2.
[8] D. P. Cardinali, “Are melatonin doses employed clinically adequate for melatonin-induced cytoprotection?,” Melatonin Res., vol. 2, no. 2, pp. 106–132, 2019, doi: 10.32794/mr11250025.
[9] I. J. C. Heart et al., “Assessment of pulmonary artery pressure by echocardiography — A comprehensive review,” IJCHA, vol. 12, pp. 45–51, 2016, doi: 10.1016/j.ijcha.2016.05.011.
[10] M. J. Nchabeleng, M. H. K. Hamese, and T. S. Ntuli, “Prevalence and outcomes of persistent pulmonary hypertension of the newborn in a neonatal unit, mankweng hospital, Limpopo Province, South Africa,” SAJCH South African J. Child Heal., vol. 15, no. 2, pp. 103–106, 2021, doi: 10.7196/SAJCH.2021.v15.i2.1773.
[11] S. Alhumaid et al., “International treatment outcomes of neonates on extracorporeal membrane oxygenation (ECMO) with persistent pulmonary hypertension of the newborn (PPHN): a systematic review,” J. Cardiothorac. Surg., vol. 19, no. 1, 2024, doi: 10.1186/s13019-024-03011-3.
[12] J. Dillard, L. R. Pavlek, S. Korada, and B. Chen, “Worsened short-term clinical outcomes in a cohort of patients with iNO-unresponsive PPHN: a case for improving iNO responsiveness,” J. Perinatol., vol. 42, no. 1, pp. 37–44, 2022, doi: 10.1038/s41372-021-01228-x.
[13] M. Kaji Yazdi et al., “Prospective Study of Neonates with Persistent Pulmonary Hypertension of the Newborn: Prevalence, Clinical Outcomes, and Risk Factors,” Iran. J. Neonatol., vol. 2, no. 2, p. 13, 2022, doi: 10.22038/IJN.2022.59465.2128.
[14] Z. Tang, M. Jiang, Z. Ou-Yang, H. Wu, S. Dong, and M. Hei, “High mobility group box 1 protein (HMGB1) as biomarker in hypoxia-induced persistent pulmonary hypertension of the newborn: a clinical and in vivo pilot study,” Int. J. Med. Sci., vol. 16, no. 8, p. 1123, 2019, doi: 10.7150/IJMS.34344.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
